Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
30 September 2023 - 7:00AM
Business Wire
Novocure (NASDAQ: NVCR) today announced its participation in the
upcoming American Society for Radiation Oncology (ASTRO) 2023
Annual Meeting from October 1 – 4 in San Diego. Presentations will
describe preclinical, clinical and simulation modeling studies on
Tumor Treating Fields (TTFields) therapy, including new insights
about methods to optimize TTFields intensities delivered at the
target tumor during treatment.
Highlights of Novocure’s poster presentations include:
- a new process to identify optimized, personalized TTFields
array layouts for each patient with glioblastoma (GBM) using
segmentation-based treatment planning (SBTP) software
- retrospective, simulated testing of SBTP to compare outputs
from array layouts generated with SBTP versus array layouts
generated with NovoTAL, the current standard treatment planning
software, with results suggesting that SBTP-generated layouts meet
established treatment thresholds for TTFields therapy, and could
potentially lead to improved clinical outcomes for patients with
GBM
- a simulation study evaluating the effects of body mass index
(BMI) on field intensities delivered to the lungs with TTFields
therapy. Results support the feasibility of TTFields therapy
delivery to the lungs regardless of BMI and highlight the
importance of choosing the appropriate array size for each
patient.
“We are committed to continuous innovation, and we look forward
to sharing new insights about the use of TTFields therapy with the
scientific community,” said Pritesh Shah, Novocure’s Chief Growth
Officer. “By developing segmentation-based treatment planning
software to optimize array placement and exploring how factors such
as array size affect the delivery of TTFields therapy, we aim to
advance our therapy as we pursue our mission to extend survival in
some of the most aggressive forms of cancer.”
Presentations on TTFields at the 2023 ASTRO Annual Meeting will
include:
- The Effect of Body Mass Index on Tumor Treating Fields
(TTFields) Intensity Distribution in the Lungs. Presenter:
Nadav Shapira. 4:45 p.m. – 6 p.m. PT on Sunday, Oct. 1.
- Patient-Specific Segmentation-Based Treatment Planning vs.
NovoTAL for TTFields Therapy in Glioblastoma. Presenter: Brian
Berger. 10:45 a.m. – 12 p.m. PT on Monday, Oct. 2.
- Retrospective Review of the Factors Limiting Optune
Initiation in GBM patients. Presenter: Luis Carranza Pena.
10:45 a.m. – 12 p.m. PT on Monday, Oct. 2.
- Tumor Treating Fields (TTFields) in the Real World for Newly
Diagnosed Glioblastoma: A Survival Meta-analysis With Systematic
Review. Presenter: Matthew Ballo. 10:45 a.m. – 12 p.m. PT on
Monday, Oct. 2.
- Compatibility of Topical Products to Manage Skin Irritation
Associated With TTFields. Presenter: Narasimha Kumar Karanam.
2:30 p.m. – 3:45 p.m. PT on Tuesday, Oct. 3.
- A Working TTFields Therapy Framework for Patient-Specific
Segmentation-Based Treatment Planning and Dosimetry. Presenter:
Brian Berger. 12:30 p.m. – 1:45 p.m. PT on Wednesday, Oct. 4.
- Alternating Tumor Treating Fields Layouts for Effective
Treatment of the Epigastric Region. Presenter: Nadav Shapira.
12:30 p.m. – 1:45 p.m. PT on Wednesday, Oct. 4.
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert
physical forces to kill cancer cells via a variety of mechanisms.
TTFields do not significantly affect healthy cells because they
have different properties (including division rate, morphology, and
electrical properties) than cancer cells. The multiple, distinct
mechanisms of TTFields therapy work together to selectively target
and kill cancer cells. Due to its multimechanistic actions,
TTFields therapy can be added to cancer treatment modalities in
approved indications and demonstrates enhanced effects across solid
tumor types when used with chemotherapy, radiotherapy, immune
checkpoint inhibition, or PARP inhibition in preclinical models.
TTFields therapy provides clinical versatility that has the
potential to help address treatment challenges across a range of
solid tumors. To learn more about Tumor Treating Fields therapy and
its multifaceted effect on cancer cells, visit
tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical trial progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2023, and subsequent filings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230929405589/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
610-723-7427
Media: Leigh Labrie media@novocure.com 610-723-7428
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024